{"id":937293,"date":"2026-02-17T12:01:17","date_gmt":"2026-02-17T17:01:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/"},"modified":"2026-02-17T12:01:17","modified_gmt":"2026-02-17T17:01:17","slug":"nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/","title":{"rendered":"Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026"},"content":{"rendered":"
\n

TEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) — Nasus Pharma Ltd.\u00a0(NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that upcoming data for NS002, the Company\u2019s investigational intranasal epinephrine powder formulation, will be presented at AAAAI 2026 Annual Meeting, taking place in Philadelphia, PA, USA, February 27 to March 2. <\/p>\n

\u201cWe are excited to share data highlighting NS002\u2019s potential for superior epinephrine absorption and robust formulation stability,\u201d said Dan Teleman, Chief Executive Officer of Nasus Pharma. \u201cDesigned as a needle-free intranasal powder, NS002 aims to deliver epinephrine more rapidly in emergency situations, and the data being presented underscore the potential advantages of the powder technology. We believe NS002 represents a unique and potentially superior differentiated epinephrine delivery option for the treatment of anaphylaxis, where seconds truly matter.\u201d <\/p>\n

\n Presentation details:<\/b>\n <\/p>\n\n\n\n\n\n\n\n\n
\n

\n Nasal epinephrine spray for anaphylaxis: which is better – powder or liquid? Nasal powder has significantly higher deposition in the nasal cavity in comparison to liquid nasal spray which could lead to enhanced blood absorption<\/span>\n <\/p>\n<\/td>\n

\n

\n Title:<\/b>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Poster presentation<\/span>\n <\/p>\n<\/td>\n

\n

\n Format<\/b>:<\/p>\n<\/td>\n<\/tr>\n

\n

\n Tair Lapidot, PhD, VP R&D and Clinical Development, Nasus Pharma<\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Corresponding author<\/b>:<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Anaphylaxis and Venom Allergy<\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Session<\/b>:<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

March 1, 2026, at 9:45-10:45 AM<\/p>\n<\/td>\n

\n

\n
\n Session date and time:<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n 592<\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Poster ID:<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Convention Center, Level 2, Hall E<\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Location:<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table>\n

###<\/p>\n\n\n\n\n\n\n\n\n
\n

\n FMXIN002 Epinephrine Intranasal Powder Spray is Stable Throughout 3 Freeze-Thaw Cycles<\/span>\n <\/p>\n<\/td>\n

\n

\n Title:<\/b>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Poster presentation<\/span>\n <\/p>\n<\/td>\n

\n

\n Format<\/b>:<\/p>\n<\/td>\n<\/tr>\n

\n

\n Tair Lapidot, PhD, VP R&D and Clinical Development, Nasus Pharma<\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Corresponding author<\/b>:<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Anaphylaxis and Venom Allergy<\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Session<\/b>:<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

March 1, 2026, at 9:45-10:45 AM<\/p>\n<\/td>\n

\n

\n
\n Session date and time:<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n 593<\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Poster ID:<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Convention Center, Level 2, Hall E<\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Location:<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n About Nasus Pharma<\/b>
\n
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products\u00a0addressing acute medical conditions in the community. NS002, Nasus\u2019 intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis.\u00a0Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers\u00a0needle-free, easy-to-use alternatives. Nasus\u2019 proprietary powder-based intranasal (\u201cPBI\u201d) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity\u2019s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit\u00a0www.nasuspharma.com<\/a>\u00a0or follow on\u00a0Twitter (X)<\/a>\u00a0or\u00a0Linked<\/a>I<\/a>n<\/a>.<\/p>\n

\n Forward Looking Statements<\/b>
\n
This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill\u201d, \u201cwould,\u201d or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nasus Pharma is using forward looking statements in this press release when it discusses: the potential of NS002 for superior epinephrine absorption; its aim to deliver epinephrine more rapidly in emergency situations; and the belief that NS002 represents a unique and potentially superior differentiated epinephrine delivery option for the treatment of anaphylaxis. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Forward-looking statements are based on the Company\u2019s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled \u201cRisk Factors\u201d in the Company\u2019s prospectus dated August 12, 2025 filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.<\/p>\n

\n Company Contact<\/b>
\n
Nasus Pharma Ltd.
info@nasuspharma.com<\/a><\/p>\n

\n Investor Contact<\/b>
\n
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

TEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) — Nasus Pharma Ltd.\u00a0(NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that upcoming data for NS002, the Company\u2019s investigational intranasal epinephrine powder formulation, will be presented at AAAAI 2026 Annual Meeting, taking place in Philadelphia, PA, USA, February 27 to March 2. \u201cWe are excited to share data highlighting NS002\u2019s potential for superior epinephrine absorption and robust formulation stability,\u201d said Dan Teleman, Chief Executive Officer of Nasus Pharma. \u201cDesigned as a needle-free intranasal powder, NS002 aims to deliver epinephrine more rapidly in emergency situations, and the data being presented underscore the potential advantages of the powder technology. We believe NS002 … <\/p>\n

Continue reading “Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-937293","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) — Nasus Pharma Ltd.\u00a0(NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that upcoming data for NS002, the Company\u2019s investigational intranasal epinephrine powder formulation, will be presented at AAAAI 2026 Annual Meeting, taking place in Philadelphia, PA, USA, February 27 to March 2. \u201cWe are excited to share data highlighting NS002\u2019s potential for superior epinephrine absorption and robust formulation stability,\u201d said Dan Teleman, Chief Executive Officer of Nasus Pharma. \u201cDesigned as a needle-free intranasal powder, NS002 aims to deliver epinephrine more rapidly in emergency situations, and the data being presented underscore the potential advantages of the powder technology. We believe NS002 … Continue reading "Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-17T17:01:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2NDg0NyM0MDIzMzMwNTQjNzAwMDI2NDE1\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026\",\"datePublished\":\"2026-02-17T17:01:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\\\/\"},\"wordCount\":682,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE2NDg0NyM0MDIzMzMwNTQjNzAwMDI2NDE1\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\\\/\",\"name\":\"Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE2NDg0NyM0MDIzMzMwNTQjNzAwMDI2NDE1\",\"datePublished\":\"2026-02-17T17:01:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE2NDg0NyM0MDIzMzMwNTQjNzAwMDI2NDE1\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE2NDg0NyM0MDIzMzMwNTQjNzAwMDI2NDE1\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/","og_locale":"en_US","og_type":"article","og_title":"Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 - Market Newsdesk","og_description":"TEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) — Nasus Pharma Ltd.\u00a0(NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that upcoming data for NS002, the Company\u2019s investigational intranasal epinephrine powder formulation, will be presented at AAAAI 2026 Annual Meeting, taking place in Philadelphia, PA, USA, February 27 to March 2. \u201cWe are excited to share data highlighting NS002\u2019s potential for superior epinephrine absorption and robust formulation stability,\u201d said Dan Teleman, Chief Executive Officer of Nasus Pharma. \u201cDesigned as a needle-free intranasal powder, NS002 aims to deliver epinephrine more rapidly in emergency situations, and the data being presented underscore the potential advantages of the powder technology. We believe NS002 … Continue reading \"Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-17T17:01:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2NDg0NyM0MDIzMzMwNTQjNzAwMDI2NDE1","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026","datePublished":"2026-02-17T17:01:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/"},"wordCount":682,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2NDg0NyM0MDIzMzMwNTQjNzAwMDI2NDE1","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/","name":"Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2NDg0NyM0MDIzMzMwNTQjNzAwMDI2NDE1","datePublished":"2026-02-17T17:01:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2NDg0NyM0MDIzMzMwNTQjNzAwMDI2NDE1","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE2NDg0NyM0MDIzMzMwNTQjNzAwMDI2NDE1"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-to-present-data-highlighting-superior-nasal-deposition-and-stability-of-intranasal-epinephrine-powder-at-aaaai-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=937293"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937293\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=937293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=937293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=937293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}